Zacks: Analysts Expect Pfizer Inc. (PFE) to Post $0.75 Earnings Per Share

Brokerages expect Pfizer Inc. (NYSE:PFE) to report earnings of $0.75 per share for the current fiscal quarter, according to Zacks. Three analysts have provided estimates for Pfizer’s earnings. The lowest EPS estimate is $0.72 and the highest is $0.78. Pfizer posted earnings of $0.67 per share in the same quarter last year, which would indicate a positive year over year growth rate of 11.9%. The firm is expected to issue its next quarterly earnings results before the market opens on Tuesday, October 30th.

On average, analysts expect that Pfizer will report full year earnings of $2.99 per share for the current fiscal year, with EPS estimates ranging from $2.95 to $3.03. For the next year, analysts expect that the company will report earnings of $3.09 per share, with EPS estimates ranging from $2.99 to $3.15. Zacks Investment Research’s EPS calculations are an average based on a survey of sell-side analysts that cover Pfizer.

Pfizer (NYSE:PFE) last posted its quarterly earnings results on Tuesday, July 31st. The biopharmaceutical company reported $0.81 EPS for the quarter, topping the consensus estimate of $0.74 by $0.07. Pfizer had a return on equity of 25.35% and a net margin of 42.35%. The business had revenue of $13.47 billion for the quarter, compared to analyst estimates of $13.30 billion. During the same quarter in the previous year, the firm earned $0.67 EPS. The company’s quarterly revenue was up 4.4% compared to the same quarter last year.

Several research firms have recently commented on PFE. Cantor Fitzgerald set a $45.00 price target on Pfizer and gave the stock a “buy” rating in a report on Monday, August 27th. JPMorgan Chase & Co. restated a “buy” rating on shares of Pfizer in a report on Tuesday, July 31st. Goldman Sachs Group restated a “neutral” rating and issued a $42.00 price objective on shares of Pfizer in a report on Wednesday, August 1st. Zacks Investment Research lowered shares of Pfizer from a “buy” rating to a “hold” rating in a report on Monday, August 6th. Finally, Deutsche Bank set a $45.00 price objective on shares of Pfizer and gave the company a “buy” rating in a report on Tuesday, August 21st. Two investment analysts have rated the stock with a sell rating, twelve have given a hold rating and nine have issued a buy rating to the stock. Pfizer presently has a consensus rating of “Hold” and a consensus target price of $41.89.

In other Pfizer news, CEO Ian C. Read sold 486,753 shares of Pfizer stock in a transaction dated Monday, July 16th. The stock was sold at an average price of $37.36, for a total value of $18,185,092.08. Following the completion of the transaction, the chief executive officer now directly owns 1,145,693 shares of the company’s stock, valued at approximately $42,803,090.48. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, insider Laurie J. Olson sold 10,214 shares of Pfizer stock in a transaction dated Monday, August 13th. The shares were sold at an average price of $41.00, for a total value of $418,774.00. Following the completion of the transaction, the insider now directly owns 72,672 shares of the company’s stock, valued at $2,979,552. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 761,230 shares of company stock valued at $29,054,690. 0.06% of the stock is currently owned by corporate insiders.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in PFE. Exeter Financial LLC grew its position in shares of Pfizer by 3.9% during the second quarter. Exeter Financial LLC now owns 31,817 shares of the biopharmaceutical company’s stock worth $1,154,000 after buying an additional 1,195 shares in the last quarter. Smart Portfolios LLC grew its position in shares of Pfizer by 43.9% during the second quarter. Smart Portfolios LLC now owns 3,935 shares of the biopharmaceutical company’s stock worth $143,000 after buying an additional 1,200 shares in the last quarter. Private Capital Group LLC grew its position in shares of Pfizer by 4.8% during the second quarter. Private Capital Group LLC now owns 26,685 shares of the biopharmaceutical company’s stock worth $968,000 after buying an additional 1,215 shares in the last quarter. Andesa Financial Management Inc. grew its position in shares of Pfizer by 6.0% during the second quarter. Andesa Financial Management Inc. now owns 21,636 shares of the biopharmaceutical company’s stock worth $785,000 after buying an additional 1,226 shares in the last quarter. Finally, Texas Yale Capital Corp. grew its position in shares of Pfizer by 1.5% during the second quarter. Texas Yale Capital Corp. now owns 83,436 shares of the biopharmaceutical company’s stock worth $3,027,000 after buying an additional 1,255 shares in the last quarter. 68.91% of the stock is owned by institutional investors.

NYSE PFE opened at $43.93 on Friday. Pfizer has a 52 week low of $33.20 and a 52 week high of $44.46. The company has a debt-to-equity ratio of 0.41, a quick ratio of 0.91 and a current ratio of 1.16. The firm has a market cap of $262.28 billion, a PE ratio of 15.35, a P/E/G ratio of 2.23 and a beta of 0.96.

The company also recently announced a quarterly dividend, which was paid on Tuesday, September 4th. Shareholders of record on Friday, August 3rd were given a $0.34 dividend. This represents a $1.36 annualized dividend and a yield of 3.10%. The ex-dividend date of this dividend was Thursday, August 2nd. Pfizer’s dividend payout ratio is currently 51.32%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It operates in two segments, Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). The IH segment focuses on the development and commercialization of medicines and vaccines, and consumer healthcare products in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases, as well as consumer healthcare, such as over-the-counter brands comprising dietary supplements, pain management, gastrointestinal, and respiratory and personal care.

Featured Article: Average Daily Trade Volume – What It Means In Stock Trading

Get a free copy of the Zacks research report on Pfizer (PFE)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply